@article{fdi:010054080,
  title = {{A} biregional survey and review of first-line treatment failure and second-line paediatric antiretroviral access and use in {A}sia and southern {A}frica},
  author = {{S}aphonn, {V}. and {S}aramony, {S}. and {V}ibol, {U}. and {S}ophan, {S}. and {T}ucker, {J}. and {Z}hang, {F}. {J}. and {H}an, {N}. and {K}umarasamy, {N}. and {S}aghayam, {S}. and {K}urniati, {N}. and {M}uktiarti, {D}. and {F}ong, {S}. {M}. and {T}hien, {M}. and {Y}usoff, {N}. {K}. {N}. and {H}ai, {L}. {C}. and {R}azali, {K}. and {R}ahman, {N}. {F}. {A}. and {N}allusamy, {R}. and {C}han, {K}. {C}. and {S}irisanthana, {V}. and {A}urpibul, {L}. and {H}ansudewechakul, {R}. and {K}hongponoi, {A}. and {L}umbiganon, {P}. and {K}osalaraksa, {P}. and {J}ourdain, {G}onzague and {A}nanworanich, {J}. and {S}uwanlerk, {T}. and {C}hokephaibulkit, {K}. and {W}ittawatmongkol, {O}. and {T}ruong, {H}. {K}. and {M}ai, {D}. {A}. {N}. and {D}o, {C}. {V}. and {H}a, {M}. {T}. and {B}ui, {H}. {V}. and {N}guyen, {V}. {L}. and {L}e, {O}. {N}. and {S}ohn, {A}. {H}. and {M}esserschmidt, {L}. and {P}ang, {J}. and {C}ooper, {D}. {A}. and {L}aw, {M}. {G}. and {K}ariminia, {A}. and {D}avies, {M}. {A}. and {E}ley, {B}. and {G}iddy, {J}. and {M}oultrie, {H}. and {P}ascoe, {M}. and {R}abie, {H}. and {T}echnau, {K}. and {V}an {C}utsem, {G}. and {V}az, {P}. and {W}eigel, {R}. and {W}ood, {R}.},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground: {T}o better understand the need for paediatric second-line antiretroviral therapy ({ART}), an {ART} management survey and a cross-sectional analysis of second-line {ART} use were conducted in the {TREAT} {A}sia {P}aediatric {HIV} {O}bservational {D}atabase and the {I}e{DEA} {S}outhern {A}frica ({I}nternational {E}pidemiologic {D}atabases to {E}valuate {AIDS}) regional cohorts. {M}ethods: {S}urveys were conducted in {A}pril 2009. {A}nalysis data from the {A}sia cohort were collected in {M}arch 2009 from 12 centres in {C}ambodia, {I}ndia, {I}ndonesia, {M}alaysia, and {T}hailand. {D}ata from the {I}e{DEA} {S}outhern {A}frica cohort were finalized in {F}ebruary 2008 from 10 centres in {M}alawi, {M}ozambique, {S}outh {A}frica and {Z}imbabwe. {R}esults: {S}urvey responses reflected inter-regional variations in drug access and national guidelines. {A} total of 1301 children in the {TREAT} {A}sia and 4561 children in the {I}e{DEA} {S}outhern {A}frica cohorts met inclusion criteria for the cross-sectional analysis. {T}en percent of {A}sian and 3.3% of {A}frican children were on second-line {ART} at the time of data transfer. {M}edian age (interquartile range) in months at second-line initiation was 120 (78-145) months in the {A}sian cohort and 66 (29-112) months in the southern {A}frican cohort. {R}egimens varied, and the then current {W}orld {H}ealth {O}rganization-recommended nucleoside reverse transcriptase combination of abacavir and didanosine was used in less than 5% of children in each region. {C}onclusions: {I}n order to provide life-long {ART} for children, better use of current first-line regimens and broader access to heat-stable, paediatric second-line and salvage formulations are needed. {T}here will be limited benefit to earlier diagnosis of treatment failure unless providers and patients have access to appropriate drugs for children to switch to.},
  keywords = {},
  booktitle = {},
  journal = {{J}ournal of the {I}nternational {A}ids {S}ociety},
  volume = {14},
  numero = {},
  pages = {7},
  ISSN = {1758-2652},
  year = {2011},
  DOI = {10.1186/1758-2652-14-7},
  URL = {https://www.documentation.ird.fr/hor/fdi:010054080},
}